This article is more than 5 years old. Information may no longer be current.

VIDEO: Expert highlights evolution, pipeline of lipid-altering medications

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOCA RATON, Fla. — The pipeline of lipid-altering medications continues to evolve and the future of CVD prevention and therapeutics is rapidly changing, Seth J. Baum, MD, FASPC, FACC, FACPM, FAHA, FNLA, president of the American Society for Preventive Cardiology, said in this video exclusive.

Baum discusses the change from a “shotgun approach to medicine” to more of a “laser beam approach to medicine” with regard to lipid-altering medications.

From human monoclonal antibodies and small interfering RNA drugs to antisense oligonucleotides and gene therapy, “it is a very exciting time in CVD prevention and therapeutics,” he said. Baum is medical director of Women’s Preventive Cardiology at the Christine E. Lynn Women’s Health and Wellness Institute at Boca Raton Regional Hospital; affiliate associate professor of clinical biomedical science in the department of integrated medicines at Florida State University’s Charles E. Schmidt College of Medicine; and founder and chief medical officer of Excel Medical Clinical Trials, LLC.